Key Takeaways Medevise Consulting will host an ophthalmic surgical robotics workshop October 8 during AAO 2026 in New Orleans ...

Both Zenkuda and tabirafusp-ted met the phase 3 DAYBREAK primary endpoints, achieving noninferiority to aflibercept for vision gains at 1 year in patients with wet AMD Kodiak reported that 54% of ...

Claris Biotherapeutics will relocate its headquarters from Jersey City, New Jersey, to South San Francisco, California, effective October 2026 The company plans to begin pivotal studies of CSB-001 ...

Zeiss expanded its Retina Workflow at EURETINA with new technologies spanning retinal imaging, surgical visualization and vitreoretinal surgery The new Alta Duo 300 combines automated OCT and fundus ...

The FDA has approved RayOne Galaxy and RayOne Galaxy Toric for commercial availability in the US The non-diffractive spiral optic is designed to provide a continuous range of vision while minimizing ...

EssilorLuxottica and Meta unveiled Ray-Ban Meta Audio and Ray-Ban Meta Gen 3 as they expand their AI eyewear portfolio to more than 100 styles by year-end Ray-Ban Meta Audio is a camera-free, ...

Cascader completed a seed financing round led by Topcon Healthcare to advance its first ophthalmic AI products toward market launch and expand its team The company's initial focus is on macular ...

Stellest 2.0 lenses showed 6-month treatment effects of 0.51 D for myopia progression and 0.21 mm for axial elongation versus single-vision lenses in an ongoing trial in China More than 90% of ...

Botond Roska, PhD, director of science at the Institute of Molecular and Clinical Ophthalmology Basel (IOB), and José-Alain Sahel, MD, distinguished professor and chairman of ophthalmology at the ...

Both 0.5-mg and 0.8-mg doses of remigromig met the primary endpoint of noninferiority to ranibizumab for mean BCVA change at 52 weeks in the phase 2b/3 BRUNELLO trial Higher rates of PDR, vitreous ...

At 6 months, third-generation Z+ IOL eyes achieved mean uncorrected visual acuity of 20/24 at distance and 20/26 at near under photopic conditions No serious adverse events or halos were reported; 79% ...